​

MoonLake Immunotherapeutics Ownership | Who Owns MoonLake Immunotherapeutics?

OverviewForecastFinancialsChartTranscripts

MoonLake Immunotherapeutics Ownership Summary

MoonLake Immunotherapeutics is owned by 102.67% institutional investors, 8.18% insiders. Bvf inc/il is the largest institutional shareholder, holding 22.45% of MLTX shares. Jupiter Merian Glb Eq AbsRet I USD Acc is the top mutual fund, with 1.65% of its assets in MoonLake Immunotherapeutics shares.

MLTX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockMoonLake Immunotherapeutics102.67%8.18%-10.84%
SectorHealthcare Stocks 244.59%12.11%-156.70%
IndustryBiotech Stocks 379.61%11.70%-291.31%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Bvf inc/il16.00M22.45%$311.54M
Deep track capital, lp7.00M9.82%$136.27M
T. rowe price investment management4.28M6.01%$83.34M
Janus henderson group3.45M5.35%$64.30M
D. e. shaw3.37M4.72%$65.53M
Cormorant asset management, lp3.21M4.50%$62.41M
Logos global management lp2.67M3.75%$52.08M
Weiss asset management lp2.58M3.62%$50.27M
Avoro capital advisors2.00M3.16%$14.34M
Citadel advisors1.97M2.77%$38.41M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Bvf inc/il16.00M7.97%$311.54M
Lion point capital, lp67.50K6.29%$1.31M
Ghost tree capital300.00K4.13%$13.19M
Cormorant asset management, lp3.21M3.20%$62.41M
Great point partners855.81K3.15%$16.66M
Acuta capital partners215.65K2.93%$4.20M
Vivo capital1.40M2.49%$27.26M
Monashee investment management75.00K2.45%$1.46M
Logos global management lp2.67M2.24%$52.08M
Exome asset management166.49K2.00%$3.24M

Top Buyers

HolderShares% AssetsChange
T. rowe price investment management4.28M0.05%4.28M
Adage capital partners gp1.50M0.02%1.50M
Janus henderson group3.45M0.03%1.36M
Logos global management lp2.67M2.24%1.18M
D. e. shaw3.37M0.03%974.85K

Top Sellers

HolderShares% AssetsChange
Avoro capital advisors2.00M0.19%-2.15M
Cormorant asset management, lp3.21M3.20%-1.27M
Westfield capital management co lp---1.26M
Federated hermes---1.25M
Alliancebernstein---1.14M

New Positions

HolderShares% AssetsChangeValue
Adage capital partners gp1.50M0.02%1.50M$10.76M
Ikarian capital435.84K0.32%435.84K$3.12M
Capricorn fund managers374.87K0.57%374.87K$7.29M
Boothbay fund management258.78K0.03%258.78K$1.86M
Burkehill global management, lp250.00K0.18%250.00K$4.87M

Sold Out

HolderChange
National bank of canada /fi/-2.00
Wpg advisers-3.00
Montag a & associates-7.00
Mai capital management-7.00
Creative financial designs inc /adv-10.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202618516.35%73,175,87416.06%1021.07%11627.47%442.33%
Mar 31, 202678-46.21%7,657,293-86.41%110.15%41-58.16%25-10.71%
Dec 31, 202517-90.17%854,269-97.72%10.04%13-85.71%3-93.33%
Sep 30, 202530-79.31%901,952-98.46%10.02%17-73.02%9-83.64%
Jun 30, 2025145-2.03%58,588,368-0.85%921.06%63-11.27%5425.58%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Jupiter Merian Glb Eq AbsRet I USD Acc1.18M1.65%1.18M
Polar Capital Biotech S Inc1.00M1.58%-
Fidelity Growth Compy Commingled Pl S981.02K1.54%273.63K
Jupiter Merian Glb Eq Abs Rt I USD Acc1.18M1.41%1.18M
Fidelity Growth Company Fund740.92K1.17%248.13K
T. Rowe Price Small-Cap Value918.59K1.10%647.15K
Federated Hermes Kaufmann R665.00K1.05%-
Federated Hermes Kaufmann Growth665.00K1.05%-
T. Rowe Price Health Sciences792.07K0.95%-147.16K
Janus Henderson Hrzn Biotec E2 USD751.22K0.88%-180.57K

Recent Insider Transactions

DateNameRoleActivityValue
Jul 27, 2026Reich Kristian Chief Scientific OfficerSell$22.00K
Jul 21, 2026Reich Kristian Chief Scientific OfficerSell$1.00M
Jul 22, 2026Reich Kristian Chief Scientific OfficerSell$48.96K
Jul 20, 2026Reich Kristian Chief Scientific OfficerSell$877.93K
Jul 15, 2026Reich Kristian Chief Scientific OfficerSell$322.26K

Insider Transactions Trends

DateBuySell
2026 Q3-8
2026 Q2-12
2026 Q1-3
2025 Q414
2025 Q3-6

MLTX Ownership FAQ

Who Owns MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics shareholders are primarily institutional investors at 102.67%, followed by 8.18% insiders and -10.85% retail investors. The average institutional ownership in MoonLake Immunotherapeutics's industry, Biotech Stocks , is 379.61%, which MoonLake Immunotherapeutics falls below.

Who owns the most shares of MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics’s largest shareholders are Bvf inc/il (16M shares, 22.45%), Deep track capital, lp (7M shares, 9.82%), and T. rowe price investment management (4.28M shares, 6.01%). Together, they hold 38.28% of MoonLake Immunotherapeutics’s total shares outstanding.

Does Blackrock own MoonLake Immunotherapeutics?

BlackRock is not among the top 10 institutional shareholders of MoonLake Immunotherapeutics.

Who is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested?

Bvf inc/il is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested, with 7.97% of its assets in 16M MoonLake Immunotherapeutics shares, valued at 311.54M$.

Who is the top mutual fund holder of MoonLake Immunotherapeutics shares?

Jupiter Merian Glb Eq AbsRet I USD Acc is the top mutual fund holder of MoonLake Immunotherapeutics shares, with 1.65% of its total shares outstanding invested in 1.18M MoonLake Immunotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools